本帖最后由 老马 于 2012-1-13 21:20 编辑
6 X) n7 Z! ~" D J
, q' D% P5 @. h1 b% O- E+ _. ~爱必妥和阿瓦斯丁的比较5 A! ?, G6 n! e- c$ _' q
4 J5 z& R* q) H. m/ q f
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
x: r! S& T& H' U/ {3 J7 f ?" W* C
* k- v3 P4 m8 W1 Q! l
& r0 J6 L# [6 N, r8 f
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ [: d8 m, B( H) ^
==================================================
* C! p k2 j1 I- K" x1 uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)! m) P$ A% F' `2 ~0 I# ?
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point., m' l; Z% W9 t0 R; [# c
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.7 W$ |$ w% R2 L9 x; s8 m# i
|